Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 15 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

15 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Nov. 8, 2019 PCRX S 10b5-1 19,448 $45.00 $875,160 16,061 Direct -54.77% Disposed -44.0% (price as of 2026-10-02)
June 5, 2019 PCRX S 10b5-1 4,114 $43.50 $178,959 11,061 Direct -27.11% Disposed -42.0% (price as of 2026-10-02)
June 4, 2019 PCRX S 10b5-1 2,852 $42.66 $121,666 15,175 Direct -15.82% Disposed -40.9% (price as of 2026-10-02)
June 4, 2019 PCRX S 10b5-1 2,074 $42.91 $88,995 18,027 Direct -10.32% Disposed -41.2% (price as of 2026-10-02)
June 3, 2019 PCRX S 10b5-1 15,510 $43.21 $670,187 20,101 Direct -43.55% Disposed -41.7% (price as of 2026-10-02)
June 4, 2018 PCRX S 1,367 $33.02 $45,138 12,226 Direct -10.06% Disposed -23.7% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Nov. 8, 2019 PCRX Stock Option (Right to Buy) Common Stock (4,750) $25.37 March 5, 2023 4,750 Disposed
Nov. 8, 2019 PCRX Stock Option (Right to Buy) Common Stock (14,698) $10.81 June 5, 2022 14,698 Disposed
June 5, 2019 PCRX Stock Option (Right to Buy) Common Stock (30,000) $43.54 June 5, 2029 30,000 Acquired
June 3, 2019 PCRX Stock Option (Right to Buy) Common Stock (12,500) $10.81 June 5, 2022 12,500 Disposed
June 3, 2019 PCRX Stock Option (Right to Buy) Common Stock (3,010) $10.52 March 2, 2022 3,010 Disposed
June 13, 2018 PCRX Stock Option (Right to Buy) Common Stock (47,250) $38.35 June 13, 2028 47,250 Acquired
May 2, 2018 PCRX Stock Option (Right to Buy) Common Stock (20,000) $34.38 May 2, 2028 20,000 Acquired
June 14, 2017 PCRX Stock Option (Right to Buy) Common Stock (17,500) $44.20 June 14, 2027 17,500 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 11 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
June 16, 2017 PCRX Common Stock 4,843 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (20,000) 20,000 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (6,000) 6,000 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (6,250) 6,250 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (10,000) 10,000 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (10,000) 10,000 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (25,000) 25,000 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (14,698) 14,698 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (12,500) 12,500 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (3,010) 3,010 Direct
June 16, 2017 PCRX Stock Option (Right to Buy)→ Common Stock (7,292) 7,292 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2018 $457,692 $250,000 $302,006 $1,230,807 · · $26,045 $2,266,550
2017 $378,462 $150,000 $386,750 $770,418 · · $966 $1,686,596

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.